Abstract: The Hall effect plasma thruster includes a main annular channel for ionization and acceleration that presents an open downstream end, at least one cathode, an annular anode concentric with the main annular channel, a pipe and a manifold for feeding the channel with ionizable gas, and a magnetic circuit for creating a magnetic field in the main annular channel. The main annular channel includes inner and outer annular wall portions delimiting the open end, each of which includes an assembly of juxtaposed conductive or semi-conductive rings in the form of laminations separated by fine layers of insulation.

Abstract: A method is described for the characterization of a tested substance, particularly useful in the study of its toxicity, and in particular immunotoxicity. Also described are cell lines and nucleic acids useful in its procurement, which may be used to embody said method, particularly in obtaining cell-chip collections destined for immunotoxicity assays.

Abstract: This invention relates to co-crystals of at least one molecule of calyx[n]arene or at least one of its derivatives, and at least one biologically active molecule, compositions and medicines including them, and the use of these co-crystals and methods used to obtain them.

Abstract: The use of Colostrinin as a medicament, particularly in the treatment of chronic disorders of the central nervous system and the immune system.

Abstract: The use of Colostrinin as a medicament, particularly in the treatment of chronic disorders of the central nervous system and the immune system.

Abstract: A process and use of at least one catalyst for phosphorylation, in particular phosphitylation, of hydroxyl groups, whereby a phosphorous compound is added to a hydroxyfunctional compound having at least one hydroxyl group. The addition yields a phosphorylated product having at least one O—P bond. The catalyst employed in the process is of the general formula (R1)nX(R2)4−n, wherein each R1 independently is hydrogen, at least one hydrocarbyl, amino, halogenated and/or silylated hydrocarbyl group, X is Si, Ge or Sn, each R2 independently is a leavening group and is F, Cl, Br, I or a sulphonate group optionally being halogen substituted and wherein n is 1, 2 or 3.

Abstract: Methods and compounds are provided for solid phase synthesis of oligonucleotides and related polymers by condensing protected monomer-O-?1,3,2-dichalcogen-substituted-phospholane! synthons in the presence of a catalytic base. Compounds of the invention include 2-N-substituted-1,3,2-dichalcogen-substituted-phospholane precursors of the above synthons, the protected monomer-O-?1,3,2-dichalcogen-substituted-phospholane! synthons, and P-chiral oligonucleotides and related P-chiral polymers.

Abstract: Methods and compounds are provided for solid phase synthesis of oligonucleotides and related polymers by condensing protected monomer-O-[1,3,2-dichalcogen-substituted-phospholane] synthons in the presence of a catalytic base. Compounds of the invention include 2-N-substituted-1,3,2-dichalcogen-substituted-phospholane precursors of the above synthons, the protected monomer-O-[1,3,2-dichalcogen-substituted-phospholane] synthons, and P-chiral oligonucleotides and related P-chiral polymers.

Abstract: Methods and compounds are provided for solid phase synthesis of oligonucleotides and related polymers by condensing protected monomer-O- 1,3,2-dichalcogen-substituted-phospholane! synthons in the presence of a catalytic base. Compounds of the invention include 2-N-substituted-1,3,2-dichalcogen-substituted-phospholane precursors of the above synthons, the protected monomer-O- 1,3,2-dichalcogen-substituted-phospholane! synthons, and P-chiral oligonucleotides and related P-chiral polymers.

Abstract: Methods and compounds are provided for solid phase synthesis of oligonucleotides and related polymers by condensing protected monomer-O-[1,3,2-dichalcogen-substituted-phospholane] synthons in the presence of a catalytic base. Compounds of the invention include 2-N-substituted-1,3,2-dichalcogen-substituted-phospholane precursors of the above synthons, the protected monomer-O-[1,3,2-dichalcogen-substituted-phospholane] synthons, and P-chiral oligonucleotides and related P-chiral polymers.